Telomir Pharmaceuticals (TELO) was upgraded by Zacks Research to "hold".
Telomir Pharmaceuticals (NASDAQ:TELO) was upgraded by analysts at
Wall S
Telomir Pharmaceuticals (NASDAQ:TELO) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Telomir Pharmaceuticals (NASDAQ:TELO) is now covered by analysts at Rodman & Renshaw. They set a "buy" rating on the stock.
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models [Yahoo! Finance]